Drug intelligence / Profile preview

F527

Development stage: Phase 1
Lead developer: Shandong New Time Pharmaceutical
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

F527 is a recombinant humanized monoclonal antibody targeting CD47, developed by Shandong New Time Pharmaceutical for the treatment of relapsed or refractory lymphoma. The drug acts as a CD47 inhibitor, aiming to block the "don't eat me" signal that cancer cells use to evade phagocytosis by macrophages. By inhibiting CD47, F527 is designed to enhance the immune system's ability to recognize and destroy malignant cells. As of April 2022, preclinical studies are ongoing in China and a phase I clinical trial was planned for patients with relapsed/refractory lymphoma[1][3][4].

Other names: F-527F527F 527

Targets

CD47 (Cluster of Differentiation 47)

Beyond the preview

Go deeper on F527.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on F527.

Explore the full profile